An explorative study on proteomic analyses related to inflammation and pain in children with juvenile idiopathic arthritis

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease during childhood. JIA is an umbrella term used to describe a heterogeneous autoimmune disease comprising seven categories, all presenting with an arthritis for at least six weeks with onset before 16 years of age [1].

Many cells and proteins are involved in the inflammatory and pain processes in JIA. Some proteins are well-studied in JIA-related inflammation, e.g., tumor necrosis factor alpha (TNFα), IL-1, IL-6, and the S100 proteins. The IL-6 is a pleiotropic cytokine that mediates acute phase reactions and is produced in a number of different cells. The S100 proteins, S100A12 and S100A8/9, originate from neutrophils and monocytes and are studied for disease activity in JIA [2, 3]. They have also been studied as possible indicators of risk of reactivation, without convincing results [4].

In addition to control of inflammation, a key goal of JIA treatment is to reduce pain, yet assessment of pain has not been incorporated in composite outcome measures for JIA [5]. The mechanism of pain in JIA is not fully understood and the experience of pain is related to many factors, for example disease activity, psychosocial situation, comorbidity, and quality of sleep. Many components are involved in the pain signaling system and so far there are no known specific biomarkers for pain in JIA. When monitoring disease activity, the focus has been on identifying biomarkers involved in inflammation. Inflammatory biomarkers in arthritis are often also described to relate to degree of pain, but children with JIA commonly report pain even when there are no signs of inflammatory activity [6, 7].

Studies analyzing multiple proteins/cytokines in JIA are rare and focused mainly on systemic JIA [8, 9]. Cytokine patterns most likely differ between the six disease categories, excepting the systemic category, but we have no knowledge of the extent to which they do so. In a study by Brescia et al., significant differences were observed in levels of cytokines associated with inflammation in synovial fluid samples from children with JIA compared to controls [10]. One study using liquid chromatography/mass spectrometry analyzed the serum proteome in 15 children with JIA and found 14 inflammatory and non-inflammatory proteins correlating significantly with clinical pain severity [11].

We used the inflammatory proteomics panel by Olink [12] to analyze concentrations of 92 proteins involved in a wide range of biological processes in inflammation and related the results to disease activity and pain in children with JIA.

Demographic data of study participants is presented in Table 1. The 51 children with JIA had a median age at inclusion of 10.4 years. Six of the seven categories of the International League of Associations for Rheumatology were represented. Eighteen of the 51 children had follow-up examinations at a Md of 7 (IQR 5.2–8.8) months. The medical treatment at the time of follow-up examination is presented, but not the medical treatments given between baseline and follow-up. Clinical and conventional laboratory variables are presented in Additional Table 1. During follow-up, JADAS27 decreased from Md 11.3 (IQR 7.4–18.9) to 2.6 (IQR 0.3–3.7), p < 0.001. The E-SR decreased in the 18 children from Md 24.0 (IQR 9.5–41.5) to Md 7.5 (IQR 2.0–10.8) mm, p < 0.001. Levels of pain and JADAS27 in the different disease categories are shown in Additional Table 2. Figure 1 shows the six proteins differing most significantly in NPX values, adjusted for multiple testing, between the 51 children with JIA in an active inflammatory state and controls: IL-6, S100A12, monocyte chemotactic protein-3 (MCP-3), oncostatin M (OSM), hepatocyte growth factor (HGF) and glial cell line derived neurotrophic factor (GDNF). Additional Table 3 presents all 19 proteins differing significantly in NPX values between the 51 children with JIA in an active inflammatory state and controls. The results were significant even after adjustment for multiple testing. The 18 healthy children had a lower age at inclusion than the 51 children with JIA, but after adjusting for age, using linear regression analyses, there was still a significant difference between groups (Additional Table 4). Because of a skewed gender distribution in children with JIA compared to controls with only three girls in the control group, we performed an analysis using linear regression in the two groups of boys, 17 with JIA and 15 healthy boys (Additional Table 5). The difference between boys with JIA and healthy boys remained very similar to the analysis in both genders. We also made a principal component analysis (PCA) -plot in the 51 children with JIA at inclusion and observed no clear gender-based groupings (Additional Fig. 1). The results of the entire Olink panel are presented in Additional Table 6.

The 14 most significant differences in plasma levels of proteins in paired samples from 18 children with JIA are shown in Table 2. For example, NPX values of IL-6, IL-20, and TNFSF14 decreased during medical treatment, while levels of TRANCE, TNFB and TRAIL increased significantly.

The correlations between NPX values of proteins and degree of pain (VAS) in 50 (missing in one) children with JIA, adjusted for age and gender before and after adjustment for multiple testing, are presented in Table 3. Proteins IL-18R1, TGFβ, GDNF, FGF21 and VEGFA correlated significantly with degree of pain before adjustment for multiple testing. Correlations between NPX values and JADAS27, adjusted for age and gender are presented in Table 4. The S100A12, matrix metalloproteinase-1 (MMP-1), IL-6, TNFSF14 and LIF correlated significantly with JADAS27 also after adjustment for multiple testing. The NPX value of GDNF (adjusted for age and gender) did not correlate significantly with JADAS27, correlation coefficient 0.18, adjusted p-value 0.38 from multiple testing.

All results of analyses in tables and figures are presented with corrections made for multiple testing, except the analyses of protein levels in relation to degree of pain, where we have chosen to also present unadjusted results.

Plasma levels of 19 of 92 tested proteins involved in biological processes related to inflammation were higher in 51 JIA patients at diagnosis, in a high disease activity state, than in controls. Following treatment, a decrease in levels of inflammatory proteins was observed in the 18 participants with follow-up samples. The JADAS27 reflecting disease activity correlated with several proteins. Five proteins correlated in unadjusted analyses with pain assessed on VAS (GDNF, TGFβ, IL-18R1, FGF21 and VEGFA). Levels of GDNF, a protein involved in pain processes, correlated significantly with pain VAS scores but not with JADAS27, after adjustment for age and gender.

The well-known inflammatory proteins involved in JIA, IL-6 and S100A12, were observed at higher levels in plasma samples from patients compared with controls and decreased during treatment. Plasma IL-6 levels correlated significantly with disease activity (JADAS27), findings in line with earlier results [2]. IL-6 is also the target of one of the medications used for treatment of JIA [15]. Other proteins significantly higher in plasma from children with JIA than in controls were monocyte chemotactic protein-3 (MCP-3), a protein known to mobilize monocytes involved in the inflammatory response [16], as well as oncostatin M (OSM), which has a potentially pro-inflammatory role in arthritis [17], and hepatocyte growth factor (HGF), involved in angiogenesis and tissue regeneration [18].

Levels of the cytokine IL-20, with the capacity to increase the proliferation of synovial cells and promote neutrophil chemotaxis [19] were lower in low than high disease activity, as were those of the pro-inflammatory cytokine TNFSF14, involved in T-cell homing [20]. The cytokines TRANCE, TRAIL, and TNFB increased during treatment in our study. These cytokines are all related to the TNF cytokine family and according to the manufacturers, the TNFB results could be explained by the assay measuring both unbound TNF and TNF in complex with medical agents. This has been shown in a study on rheumatoid arthritis (RA) as well [21]. The children with JIA in this study were mainly treated with a TNF-inhibitor and a folate antagonist. Modifications by methotrexate on cytokine profiles are still unclear [22] and cytokines are also to some extent dependent on each other.

As late as 18 years after onset, many patients with JIA have an ongoing active disease with high burden of medication [23]. Pain in JIA is associated with fatigue leading to functional difficulties [6, 24, 25]. Pain and fatigue decrease a child’s ability to participate in activities like social life, school, and sports [26‐28]. Even a minimal pain reduction improves the quality of life in these children [29]. Earlier research has shown that median pressure point threshold, reflecting pain tolerance, is lower in children with JIA than in controls, also in areas of the body not close to affected joints [30, 31]. This knowledge supports an altered pain perception, indicating a damage in the peripheral nerve system, a sensitization caused by the disease process. In one study, early pain severity was associated with a more severe disease outcome 15–18 years after onset, highlighting the importance of pain in disease process [32].

Many proteins involved in the inflammatory process are recognized as important mediators of inflammatory pain [33], including proteins originating from neurons [34]. It has become apparent that there is an interaction between the immune and nervous system in steady state as well as under pathological circumstances. IL-6 is involved in inflammation as well as in the pain process [15, 35]. In our study, IL-6 correlated significantly with inflammation but not with degree of pain. Other studies have shown that IL-6 is one of the pro-inflammatory cytokines, released by stimulation of TNFα, triggering the release of the final inflammatory mediator prostaglandin E2 (PGE2) and sympathetic amines that directly sensitize the nociceptors [36]. In studies of mice, IL-6 has been shown to be directly involved in the pain process of inflammatory arthritis [37].

Interestingly, plasma GDNF levels were higher in children with JIA than controls, also after adjustment for age and gender and correlated with pain in unadjusted analyses, but not with disease activity. GDNF is found in both the peripheral and the central nervous systems, but is present mainly in the peripheral neurons, particularly in the dorsal root ganglion, and in spinal dorsal horn neurons [34]. Many cell types synthesize and secrete GDNF, including glial cells, astrocytes and oligodendrocytes, Schwann cells, motor neurons, and skeletal muscle cells [38]. GDNF is a neurotrophic factor and has been found to have a neuroprotective function in the brain, protecting dopaminergic neurons, but lately it has been found to take part in nociception and pain [34]. GDNF has been shown to have an anti-nociceptive modulating role in neuropathic pain, but in experimental models of inflammatory pain it has been seen to have a pro-nociceptive effect, which could explain our findings [34, 39].

In addition to GDNF, levels of TGFβ and IL-18R1 correlated with pain. Fibroblast-like synoviocytes from patients with JIA have presented with a dysregulated TGFβ signaling compared with controls [40]. TGFβ in plasma and cerebrospinal fluid has been shown to be a biological indicator of chronic pain in patients with osteoarthritis [41] and the pro-inflammatory protein IL18 has been shown to be associated with disease activity in RA and JIA but not specifically related to degree of pain [42, 43]. Our results relate to the receptor for IL18, IL18R1, which is essential for IL18-mediated signal transduction.

The study cohort was small and drawing of conclusions must be cautious. One must consider the difficulty in interpretation of multiple cytokines in such a heterogeneous disease. A low NPX value corresponds to a lower relative concentration of a biomarker, but the NPX value of each protein is dependent on levels of all the other proteins in the analysis [12]. When comparing plasma protein levels between groups as well as in correlation analyses between NPX-levels and pain VAS results, we corrected for age and gender. We found no obvious influence on the comparisons of either of them but this should be explored in a larger cohort.

We could only find one other study that has explored a wide panel of pain-associated proteins in JIA [11]. Since the method used and the proteins studied are different, we cannot make any comparisons, but both studies support that non-inflammatory mechanisms may be involved in the pain process of those children. Our results on several cytokines involved in inflammation in JIA are in line with earlier studies. This is supportive for our results on cytokines in relation to pain and we aim to perform more, larger studies to further evaluate our findings.

In this explorative study of plasma proteomics analyses related to inflammation and pain in JIA, we found that levels of proteins differed between children with JIA and controls, and that levels of some proteins also correlated with degree of pain, irrespective of age or gender. Levels of GDNF, originating from neural cells, correlated with degree of pain but not degree of inflammation. In the search for a pain-related biomarker in JIA that is not primarily explained by inflammation, GDNF could be a possible candidate for further studies.